Loading…

A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass

Summary Background An immature coagulation system coupled with the hypothermia and hemodilution associated with cardiopulmonary bypass (CPB) in infants makes the activated clotting time (ACT) an ineffective monitor for anticoagulation in this population. The Medtronic HMS Plus Hemostasis Management...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric anesthesia 2015-06, Vol.25 (6), p.580-586
Main Authors: Machovec, Kelly A., Jooste, Edmund H., Walczak, Richard J., Homi, Hercilia Mayumi, Jaquiss, Robert D. B., Lodge, Andrew J., Ames, Warwick A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background An immature coagulation system coupled with the hypothermia and hemodilution associated with cardiopulmonary bypass (CPB) in infants makes the activated clotting time (ACT) an ineffective monitor for anticoagulation in this population. The Medtronic HMS Plus Hemostasis Management System (HMS; Medtronic, Inc., Minneapolis, MN, USA) is shown to decrease thrombin generation and blood product requirements. Aim We conducted a quality improvement initiative to test our hypothesis that the use of HMS results in reduced incidence of subtherapeutic ACT values, blood product usage, and operating room time for infants undergoing cardiac surgery. Methods Fifty consecutive patients weighing
ISSN:1155-5645
1460-9592
DOI:10.1111/pan.12591